Biotechnology struggled in the public equity markets in 2023, hit by a combination of depressed investor sentiment, regulatory challenges, geopolitical tensions, and supply chain disruptions. …
June 18, 2024
The GLP-1 Gold Rush Continues
A 2024 report from GlobalData has revealed that in spite of approaching headwinds in the obesity market, glucagon-like peptide-1 (GLP-1) receptor agonists will continue to…
SLEEP 2024, this year’s joint meeting of the American Academy of Sleep Medicine (AASM) and the Sleep Research Society, was held in Houston, TX from…
NVIDIA is the third stock ever to reach a $3T market cap which has accelerated the S&P and Nasdaq to reach new record highs. Microsoft…
June 05, 2024
ASCO 2024: Breakthroughs in Breast Cancer
The American Society of Clinical Oncology (ASCO) annual meeting is one of the largest gatherings of oncology professionals globally, and this year’s event showcased numerous…
Oncocyte Corporation’s (Nasdaq: OCX) VitaGraft TM Kidney diagnostic test for transplant monitoring has been successfully utilized in a Phase 2 clinical trial published in the…
May 28, 2024
Digested Read: Breakthroughs from DDW 2024
The human digestive system contains eight organs and has its own nervous system. It can be affected by our emotions and is ruled by a…
May 23, 2024
PRISM MarketView Commends US Military and Showcases Patriotic Stock Plays in Honor of Memorial Day Weekend
As Memorial Day weekend approaches, we must remember and honor those who have served and sacrificed for our country. We thank those who have dedicated…
May 18, 2024
What’s Next in the Great GLP-1 Race?
Roche Holding (RHHBY) joined the race to commercialize its own GLP-1 (glucagon-like peptide-1) receptor agonist drug this week, announcing that its dual-agonist asset, CT-388, had…
May 11, 2024
A Changing Landscape: AI In Biotechnology
The use of artificial intelligence (AI) in biotechnology offers companies a compelling opportunity to accelerate and optimize drug development, a process that is time consuming,…
The FDA approved 55 drugs in 2023, including the highly anticipated Lecanemab by Eisai (ESAIY) and Biogen (BIIB), GSK’s (GSK) world-first vaccine for respiratory syncytial…
Glioblastoma is a complex, aggressive brain cancer that has no cure. The median length of survival following diagnosis is between 15 and 18 months, and…